Adjuvant PD-1-based therapies for high-risk resected melanomas are here to stay. Haykal T, Contreras C. Am J Surg 2024 Jun 1:115791. doi: 10.1016/j.amjsurg.2024.115791.

Read + Share

Amedeo Smart

Independent Medical Education

Haykal T, Contreras C. Adjuvant PD-1-based therapies for high-risk resected melanomas are here to stay. Am J Surg 2024 Jun 1:115791. doi: 10.1016/j.amjsurg.2024.115791.
PMID: 38845270